The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000758303p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
19/05/2026
Date registered
Help: Date registered
25/06/2026
Date last updated
Help: Date last updated
25/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
25/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
PROMPT-HPV: Personalised reminders and GP endorsed messages for Human Papillomavirus Vaccination in young people
Scientific title
Pilot randomised trial of SMS prompts in General Practice to improve uptake of Human Papillomavirus catch up vaccines in 18-25 year olds
Additional trial identifiers [1] 317083 0
Nil known
Universal Trial Number (UTN)
Trial acronym
PROMPT-HPV
Related trial records

Health condition
Health condition(s) studied:
Human papillomavirus (HPV) 341973 0
Cancer 341974 0
Condition category
Condition code
Public Health 337713 337713 0 0
Health promotion/education
Public Health 337714 337714 0 0
Health service research
Infection 337715 337715 0 0
Sexually transmitted infections
Cancer 338047 338047 0 0
Cervical (cervix)
Cancer 338048 338048 0 0
Penile (penis)
Cancer 338049 338049 0 0
Bowel - Anal
Cancer 338050 338050 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
What is the intervention
The intervention is a series of three text messages sent from a patient's general practitioner (GP) delivered at 0, 1 and 3 months. The text messages are designed to prompt the patient to access information about the HPV vaccine and, if relevant, take action to receive the vaccine.
All messages follow the same basic structure: an introduction to the patient (including their first name) and a statement to say this is their GP from Growlife Medical, then a 1-2 line 'key message' followed by a call to action (link to Growlife Medical webpage to access links to existing government and trusted resources and book a vaccine appointment) and a final line with instructions to opt out.
There are two sets of three messages. Set 1 of the key messages is designed for people aged 18-24 years. Set 2 of key messages is for those aged 25 years. The key messages for Set 1 (18-24 years) are a) information about the recipients' vaccination status, b) reminder to book the vaccine and statement on safety; and c) reminder they may have missed the vaccine and behavioural messaging with ease framing. The key messages for Set 2 (25 year olds) are a) information about the recipients' vaccination status plus a note about it only being free before they turn 26, b) reminder to book the vaccine before they turn 26 and statement on safety; and c) reminder they may have missed the vaccine, they need to book before they turn 26 and behavioural messaging with ease framing.
All messages include a link to a dedicated webpage (only accessible via the link) which includes information on how to book an HPV vaccine at Growlife Medical, some FAQs and links to external resources. The FAQs and general information were developed specifically for this study. The external resources include publicly available webpages, downloads and podcasts including but not limited to:
https://www.hpvvaccine.org.au/
https://www.health.gov.au/topics/immunisation/vaccines/human-papillomavirus-hpv-immunisation-service
Podcast about HPV vaccine: Podcast Matter of Vax. Immunisation Foundation of Australia. Released July 2023. https://www.ifa.org.au/matterofvax

Who delivers it and their relevant expertise
The text messages will be sent via GP software to eligible patients. A team including the lead GP, software developers and researchers have designed and reviewed the processes and criteria used to identify patients and send messages.

How it is delivered
The text messages will be delivered from the GP practice software to the individual patient’s mobile phone.

How often and for how long
There will be three messages delivered at 0, 1 and 3 months.

Where it is delivered
The messages are delivered from the patients GP clinic at a specified time. It is unknown where the patient will be located when they receive the message.

Adherence
The 2nd and 3rd messages will act as reminders to the first message. The software can detect if a message has been delivered successfully, this will be used to monitor the intervention delivery. Additionally, data will be collected for instances where patients contact the GP clinic and request more information about the messages or chooses to opt out from receiving the messages.
Intervention code [1] 333853 0
Behaviour
Intervention code [2] 334224 0
Prevention
Description of the comparator or control
What is the comparator
The comparator arm will not receive any messages in the first 6 months, they are a waitlist active control group. After the 6 month primary trial period, the intervention will be delivered to the comparator arm.
Who delivers it and their relevant expertise
During the first 6 months, the comparator group will receive usual care from their GP clinic team. After the crossover, the intervention will be delivered as described above. The intervention is a series of three text messages sent from a patient's general practitioner (GP) delivered at 0, 1 and 3 months. The text messages are designed to prompt the patient to access information about the HPV vaccine and, if relevant, take action to receive the vaccine.
How it is delivered
In the first 6 months, usual care will be delivered per existing arrangements. After crossover, the text messages will be delivered from the GP practice survey to the individual patient's mobile phone.
How often and for how long
There will be three messages delivered at 6, 7 and 9 months.
Where it is delivered
For the purposes of this study, usual care is defined as any care that would normally be offered or delivered. In the case of Growlife medical, they do not currently send any reminders or prompts for patients to receive the HPV vaccine, so participants in the usual care group would not receive any communication specifically about the vaccine. Under the National Immunisation Program (NIP) everyone aged 18-25 are eligible for a free single dose of HPV vaccine. It can be accessed through general practice and pharmacies or other immunisation providers. There are no changes to how this is offered to those in the usual care group.

Adherence
The messages are delivered from the patient's GP clinic at a specified time. It is unknown where the patient will be located when they receive the message.
Control group
Active

Outcomes
Primary outcome [1] 345427 0
Proportion of randomised participants with HPV vaccination documented in Electronic Medical Record (EMR)/Australian Immunisation Register (AIR) by 6 months.
Timepoint [1] 345427 0
This outcome will be assessed at baseline and 6 months post commencement for the intervention and control group.
Secondary outcome [1] 461612 0
Proportion of SMS recipients who found the SMS messages acceptable and reasons why or why not
Timepoint [1] 461612 0
This will be assessed after the 6 months post randomisation primary outcome data is collected for the intervention group. This outcome is not assessed in the control arm.
Secondary outcome [2] 461613 0
Identification of factors acting as facilitators or barriers to the implementation of the SMS intervention in practice from initiation to vaccination of the young person from the perspective of practice staff. This will be assessed as a composite outcome.
Timepoint [2] 461613 0
GP staff Survey 1 and interviews/group discussions will be assessed 6 months post randomisation. GP staff Survey 2 will be assessed 12 months post randomisation.
Secondary outcome [3] 461614 0
Identification of potential solutions or adaptations necessary for scale up. This will be assessed as a composite outcome.
Timepoint [3] 461614 0
This will be assessed 6 months post randomisation for message recipients. GP clinic staff will have this outcome assessed at 6 months post randomisation and 12 months post randomisation. For message recipients, this will be assessed after the 6 month primary outcome data is collected and before the 12 month primary outcome data is collected
Secondary outcome [4] 461615 0
Implementation cost - defined as the cost impact of an implementation effort. This will be assessed as a composite outcome.
Timepoint [4] 461615 0
Staff log of intervention activities will be collected from project start date through to date of last data collection (approximately 12 months post randomisation). GP staff Survey 1 and interviews/group discussions will be assessed 6 months post randomisation. GP staff Survey 2 will be assessed 12 months post randomisation.
Secondary outcome [5] 462862 0
Implementation fidelity - defined as the degree to which an intervention was implemented as it was prescribed in the original protocol/as it was intended. This will be assessed as a composite outcome.
Timepoint [5] 462862 0
Staff log of intervention activities will be collected from project start date through to date of last data collection (approximately 12 months post randomisation). GP staff Survey 1 and interviews/group discussions will be assessed 6 months post randomisation. GP staff Survey 2 will be assessed 12 months post randomisation.
Secondary outcome [6] 462863 0
Implementation penetration - defined as the integration of a practice within a service setting and its subsystems. This will be assessed as a composite outcome.
Timepoint [6] 462863 0
GP staff Survey 1 and interviews/group discussions will be assessed 6 months post randomisation. GP staff Survey 2 will be assessed 12 months post randomisation.
Secondary outcome [7] 462864 0
Intent for Implementation sustainability - defined as the extent to which a newly implemented treatment is maintained or institutionalized within a service setting’s ongoing, stable operations. This will be assessed as a composite outcome.
Timepoint [7] 462864 0
GP staff Survey 1 and interviews/group discussions will be assessed 6 months post randomisation. GP staff Survey 2 will be assessed 12 months post randomisation.
Secondary outcome [8] 462865 0
Proportion of newly vaccinated patients in waitlist control cohort in 12-month period following initiation of intervention aka 6-month uptake after cross-over to initial control arm.
Timepoint [8] 462865 0
This outcome will be assessed at 12 months post commencement for the control group.

Eligibility
Key inclusion criteria
Each patient must meet all the following criteria to be enrolled in this trial:
• Aged between 18 and 25 years at the time of randomisation
o All 25-year-olds will receive the intervention in phase 1. This is to avoid the risk of the group ageing out of eligibility for free vaccine before they could be offered the intervention which could happen if they were in the control arm of the trial.
• Is an active patient at the recruiting general practice (Growlife)(per RACGP definition: greater than or equal to 3 medical consultations at clinic in previous 2 years)
• Have a mobile phone number recorded in recruiting general practice (Growlife) EMR
• Be eligible to receive the HPV vaccine catch-up (under 26 years old, enrolled in Medicare, has not previously received 1 or more doses of the HPV vaccine)
Minimum age
18 Years
Maximum age
25 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Patients meeting any of the following criteria will be excluded from the trial:
• Has opted out of recruiting general practice (Growlife) research activities and/or SMS communications

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation will be concealed and centralised for the cohort. A member of the software development team is the holder of the allocation schedule. They will be located off-site and will apply the allocation via computer.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation) will be developed by a member of the software development team.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Participants aged 18-24 years will be randomised into either the intervention arm or control arm. All 25-year-olds will receive the intervention in phase 1. This is to avoid the risk of the group ageing out of eligibility for free vaccine before they could be offered the intervention which could happen if they were in the control arm of the trial. The intervention arm will receive the intervention (SMS message about HPV vaccine from their GP) at 0,1 and 3 months. The primary outcome will be measured at 6 months. Following primary outcome data collection, the control arm will receive the intervention at 6, 7 and 9 months.
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Noting that this is a pilot/proof of concept study, an initial check suggests about 1025 HPV unvaccinated 18–25-year-olds in the Growlife EMR. A manual data cleansing exercise will be required to update the Growlife database against AIR. If 25% are unvaccinated per AIR, this is 256 patients. With 128 per arm, we would be able to detect a vaccine uptake of 5.8% (vs 0% control arm) or greater (power 80%, precision 95%).
The analysis will be an intention to treat (ITT) analysis, i.e. participants will be analysed in the arm they were allocated to, regardless of if they complete the intervention (e.g. SMS did not successfully send).
The proportion of newly vaccinated patients in each arm will be calculated using the randomised population in each arm as the denominator and the number of newly vaccinated patients as the numerator.

Appropriate methods for dealing with missing endpoint data will be detailed in the statistical analysis plan, informed by a blinded review of the data. Overarching study analysis will occur considering the constructs of Proctor’s implementation outcomes.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 321674 0
Government body
Name [1] 321674 0
NHMRC Centre for Research Excellence in Cervical Cancer Control (C4)
Country [1] 321674 0
Australia
Primary sponsor type
University
Name
The University of Melbourne
Address
Country
Australia
Secondary sponsor category [1] 324730 0
None
Name [1] 324730 0
Address [1] 324730 0
Country [1] 324730 0
Other collaborator category [1] 283937 0
Commercial sector/Industry
Name [1] 283937 0
Growlife Medical
Address [1] 283937 0
Country [1] 283937 0
Australia
Other collaborator category [2] 283938 0
Commercial sector/Industry
Name [2] 283938 0
HealthIT
Address [2] 283938 0
Country [2] 283938 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320204 0
Science, Technology, Engineering, Mathematics and Medicine (STEMM 2) – Greater Than Low Risk (GTLR) committee
Ethics committee address [1] 320204 0
Ethics committee country [1] 320204 0
Australia
Date submitted for ethics approval [1] 320204 0
02/06/2026
Approval date [1] 320204 0
Ethics approval number [1] 320204 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149758 0
Prof Julia Brotherton
Address 149758 0
Level 4, 207 Bouverie Street, The University of Melbourne, Melbourne Victoria 3010
Country 149758 0
Australia
Phone 149758 0
+61390353848
Fax 149758 0
Email 149758 0
Contact person for public queries
Name 149759 0
Lucy Boyd
Address 149759 0
Level 4, 207 Bouverie Street, The University of Melbourne, Melbourne Victoria 3010
Country 149759 0
Australia
Phone 149759 0
+61 3 8344 4793
Fax 149759 0
Email 149759 0
Contact person for scientific queries
Name 149760 0
Lucy Boyd
Address 149760 0
Level 4, 207 Bouverie Street, The University of Melbourne, Melbourne Victoria 3010
Country 149760 0
Australia
Phone 149760 0
+61 3 8344 4793
Fax 149760 0
Email 149760 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: The study will not collect individual participant data for the primary outcome. Data collected will be aggregate and deidentified.
Individual participant data will be collected for the evaluation and qualitative components, however this will only be shared as summary data of all participants, not individual data to maintain participant confidentiality. This was chosen as the evaluation and qualitative components will only include a small number of participants and re-identification may be possible.




What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Study protocol  [email protected] available via email request
Ethical approval  [email protected] available via email request
Informed consent form  [email protected] available via email request


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.